U.S. markets open in 5 hours 40 minutes
  • S&P Futures

    3,942.75
    +6.00 (+0.15%)
     
  • Dow Futures

    33,666.00
    +41.00 (+0.12%)
     
  • Nasdaq Futures

    11,533.00
    +23.50 (+0.20%)
     
  • Russell 2000 Futures

    1,811.60
    +3.60 (+0.20%)
     
  • Crude Oil

    72.65
    +0.64 (+0.89%)
     
  • Gold

    1,794.30
    -3.70 (-0.21%)
     
  • Silver

    22.91
    -0.01 (-0.05%)
     
  • EUR/USD

    1.0516
    +0.0002 (+0.02%)
     
  • 10-Yr Bond

    3.4080
    0.0000 (0.00%)
     
  • Vix

    22.78
    +0.61 (+2.75%)
     
  • GBP/USD

    1.2184
    -0.0021 (-0.17%)
     
  • USD/JPY

    136.9280
    +0.4040 (+0.30%)
     
  • BTC-USD

    16,830.59
    +33.37 (+0.20%)
     
  • CMC Crypto 200

    395.30
    -6.73 (-1.67%)
     
  • FTSE 100

    7,487.96
    -1.23 (-0.02%)
     
  • Nikkei 225

    27,574.43
    -111.97 (-0.40%)
     

Autolus Therapeutics to Report Second Quarter 2022 Financial Results on August 4, 2022

Autolus Inc.
Autolus Inc.

LONDON, July 21, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its second quarter 2022 financial results and operational highlights before open of U.S. markets on Thursday, August 4, 2022.

Management will host a conference call and webcast at 8:30 am ET/1:30 pm BST to discuss the company’s financial results and provide a general business update. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are required to access the conference call.

A simultaneous audio webcast and replay will be accessible on the events section of Autolus’ website.

Contact:

Olivia Manser
+44 (0) 7780 471568
o.manser@autolus.com
Julia Wilson
+44 (0) 7818 430877
j.wilson@autolus.com

Susan A. Noonan
S.A. Noonan Communications
+1-917-513-5303
susan@sanoonan.com